EGFR and non-small cell lung carcinoma: Study OAM4558g was a randomized Phase II study in which patients with relapsed NSCLC were randomized to receive onartuzumab plus erlotinib (Tarceva®, a small-molecule inhibitor of EGFR) or erlotinib alone [62].